Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tron-Translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-University Mainz Gmb currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, NGUYEN, NGOC-ANH THI. The prosecution is occurring within 1 distinct art unit, which points to a specialized focus for the company's current patent filings. This structure indicates that the company is prioritizing a specific technical domain rather than diversifying its intellectual property across multiple biological or pharmaceutical classifications.
As the busiest examiner, NGUYEN, NGOC-ANH THI is responsible for 1 pending office action, which accounts for the total volume of the portfolio's current active cases. The presence of only 1 distinct examiner and 1 distinct art unit for the 1 pending office action indicates a highly concentrated prosecution environment. This structure means that the success of the current portfolio depends entirely on the interactions within this single art unit and with this specific examiner. Practitioners should tailor their strategy to the specific preferences of NGUYEN, NGOC-ANH THI, as there are no other active cases to provide alternative examiner perspectives or art unit experiences.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROGERS, ERIC JASON | 1 | 57.4% | +32.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18697945 | MODIFIED REPLICABLE RNA AND RELATED COMPOSITIONS AND THEIR USE | ROGERS, ERIC JASON | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18697945 | MODIFIED REPLICABLE RNA AND RELATED COMPOSITIONS AND THEIR USE | ROGERS, ERIC JASON | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18697945 | MODIFIED REPLICABLE RNA AND RELATED COMPOSITIONS AND THEIR USE | ROGERS, ERIC JASON | — | §101§102§103§112DP | Non-Final OA | — | Pending | Apr 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial